Skip to content

Recursos

Trastornos Hemorrágicos

Los trastornos hemorrágicos son un grupo de trastornos que comparten la incapacidad de formar un coágulo sanguíneo adecuado. Se caracterizan por hemorragias prolongadas tras lesiones, intervenciones quirúrgicas, traumatismos o menstruaciones. A veces la hemorragia es espontánea, sin una causa conocida o identificable. La coagulación inadecuada puede deberse a defectos en los componentes de la sangre, como las plaquetas y/o las proteínas de la coagulación, también llamadas factores de coagulación. MAS…

Centros de Tratamiento de Hemofilia

Muchas personas con trastornos hemorrágicos utilizan los recursos de su centro de tratamiento de la hemofilia (HTC, por sus siglas en inglés). Las personas que acuden a centros de tratamiento de la hemofilia no sólo encontrarán lo más novedoso en atención médica, sino que también se beneficiarán de un personal con experiencia y atento que se toma el tiempo necesario para desarrollar planes integrales de atención terapéutica para los pacientes y sus familias. MAS…

Factor Friends Newsletter

Adicional Recursos

The National Hemophilia Foundation is dedicated to finding better treatments and cures for bleeding disorders and to preventing the complications of these disorders through education, advocacy and research. MORE…

News from HFA

  • Word from Washington: August 2023

    Advocates are responding to yet another payer-side, cost-saving scheme that harms patient access to medicine. The latest version, the so-called “alternative funding program” (AFP), is a shady strategy pitched to employers that promises to lower health plan spending on specialty drugs such as bleeding disorder products and other expensive medicines. AFP vendors advise employer health The post Word from Washington: August 2023 appeared first on Hemophilia Federation of America.

  • UPDATE: Takeda to Voluntarily Replace Certain BAXJECT® II Reconstitution Devices

    UPDATE as of 8/28/2023 Takeda, in agreement with the U.S. Food and Drug Administration (FDA), has decided to voluntarily replace BAXJECT® II reconstitution devices produced by Baxter between October 2021 and January 2022 co-packaged for use in conjunction with RECOMBINATE™ [Antihemophilic Factor (Recombinant)] and RIXUBIS® [Coagulation [Factor IX (Recombinant)]. Takeda has received reports of white The post UPDATE: Takeda to Voluntarily Replace Certain BAXJECT® II Reconstitution Devices appeared first on Hemophilia Federation of America.

  • Dear Addy: In-District Legislative Meetings

    Dear Addy, With Congress in recess, how can I continue to participate in legislative advocacy? Signed, Bleeding Disorders Advocate Dear Bleeding Disorders Advocate, Every August, the United States Congress embarks on a recess, temporarily adjourning its legislative business and allowing members to return to their home states and districts. The August recess tradition serves as The post Dear Addy: In-District Legislative Meetings appeared first on Hemophilia Federation of America.

  • Word from Washington: July 2023

    July saw mounting coverage losses from the national Medicaid unwinding. As of July 28, nearly four million people have been disenrolled from Medicaid since redeterminations began in April 2023. Three-quarters of that total lost coverage for procedural reasons, i.e., paperwork, and may still be eligible for Medicaid. In response to this dismaying track record:  Also The post Word from Washington: July 2023 appeared first on Hemophilia Federation of America.

  • Dear Addy: Finding Community

    Dear Addy, I am the only person I know who has a bleeding disorder. I don’t know any other patients at my HTC, and I live pretty far away from my nearest member organization, so I don’t usually get the chance to attend community events. I want to connect with others in the community, but The post Dear Addy: Finding Community appeared first on Hemophilia Federation of America.